DNTH vs ERAS Stock Comparison

ERAS currently leads DNTH in this stock comparison, with AIQ scores of 61 vs 56. The clearest difference is quality, while DNTH has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 5 points
DNTH
Healthcare
vs
ERAS
Healthcare
DNTH
Dianthus Therapeutics, Inc.
Price
$91.81
Day move
-0.72%
AIQ Score
56/100
Best edge
Risk Resilience
Sector
Healthcare
ERAS
Erasca, Inc.
Leads
Price
$15.66
Day move
-0.76%
AIQ Score
61/100
Best edge
Quality
Sector
Healthcare

What is the main difference between DNTH and ERAS?

ERAS leads the current stock comparison as Erasca, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Dianthus Therapeutics, Inc. vs Erasca, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 59/66 fields· Moderate confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

ERAS leads

ERAS leads by 5 AIQ points, primarily on Quality and Momentum, having only recently taken the lead back from DNTH.

Fragile: 1 of 4 evidence groups support ERAS, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 1 of 4Comparison trend: Reversed
DNTH

Dianthus Therapeutics, Inc.

AIQ Score
56/100
AIQ Edge Score
9/10
ERAS

Erasca, Inc.

Leads
AIQ Score
61/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors ERAS over DNTH, 61 versus 56 as of Nov 15, 2026. ERAS's advantage is driven primarily by stronger quality and momentum, while DNTH holds the stronger risk resilience profile. ERAS also shows the stronger technical structure relative to its 50-day moving average. 1 of 4 covered evidence groups favor ERAS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5.

Compare Dianthus Therapeutics, Inc. and Erasca, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

DNTH
+734.6%
ERAS
+509.3%

Price return comparison

Growth of $10,000, price only

DNTH $83,464 · ERAS $60,934

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare DNTH and ERAS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

DNTH advantage
0
ERAS advantage
  • Risk Resilience58 vs 39
    DNTH +19
  • Quality52 vs 65
    ERAS +13
  • Momentum58 vs 67
    ERAS +9

1 of 4 evidence groups favor ERAS. ERAS’s edge is concentrated in quality and momentum; DNTH keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

DNTH0 AIQ

No factor moved materially.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.74x)
  • RSI Bearish Divergence — bearish, momentum, medium horizon
ERAS+9 AIQ

Largest factor move: Quality +21

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)

The lead changed hands: ERAS moved ahead of DNTH in the latest session.

Deeper signal detail for each name lives on its own signals page — DNTH and ERAS both carry a full feed there.

The central trade-off

ERAS (Erasca, Inc.): the stronger current systematic profile, led by quality and momentum.

DNTH (Dianthus Therapeutics, Inc.): the counter-case, on risk resilience, fundamentals, technicals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ERAS

ERAS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

DNTH

DNTH on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

ERAS

ERAS on the Momentum factor, by 9 points.

Lower downside

DNTH

DNTH on Risk Resilience, by 19 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureDNTHERASNote
Implied upside to target+46%—Level
Target dispersion0%—Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering189Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

1 of 4 covered evidence groups favor ERAS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreERAS56 vs 61
FundamentalsDNTHEPS growth 10% vs -7.1%; TTM ROE -3.8% vs -5.6%
ValuationNot coveredNot covered
TechnicalsDNTHPrice vs 50-day 3.8% vs 4.7%; vs 200-day 5.6% vs 2.6%
Risk ResilienceDNTHRisk Resilience 58 vs 39
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DNTH and ERAS and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
  • Only 1 of 4 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ERAS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5.

May 27DNTH leads above the line · ERAS leads belowNov 13
Today
ERAS +5
56 vs 61
7 sessions ago
DNTH +2
53 vs 51
30 sessions ago
DNTH +8
49 vs 41
90 sessions ago
DNTH +11
70 vs 59

The lead changed hands 3 times in this window, most recently on Nov 13 when ERAS moved ahead of DNTH.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

DNTHConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only DNTH

  • Golden Cross Active — bullish, trend, long horizon (1.75%)
  • Low Volume Rally Warning — bearish, volume, short horizon (0.74x)
  • RSI Bearish Divergence — bearish, momentum, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon
ERASConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only ERAS

  • Death Cross Active — bearish, trend, long horizon (2.00%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)
  • Beta Spike Warning — bearish, risk_regime, long horizon

Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.

ERAS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

DNTHNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.72%, AIQ 0 points).

ERASDivergence

Price is down while the AIQ Score moved up 9 points over the same session — price and model disagree (price -0.76%, AIQ +9 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1DNTH closes the Quality gap — currently 13 points behind, the largest single contributor to ERAS's edge.
  2. 2DNTH's Low Volume Rally Warning resolves — a bearish volume rule currently active against it.
  3. 3ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

DNTH leads on balance
MetricDNTHERAS
Revenue growth (YoY)59%0%
EPS growth (YoY)10%-7.1%
Gross margin97.2%0%
Operating margin-86.8%0%
Return on equity (TTM)-3.8%-5.6%
Debt to equity00.05

Performance

ERAS leads 5 of 6 windows
MetricDNTHERAS
1 week (5 sessions)6.7%8.7%
1 month (20 sessions)27.4%17%
3 months (63 sessions)-20.1%-14.3%
6 months (126 sessions)6.6%53.1%
Year to date122.8%321%
1 year (252 sessions)137.1%490.9%

Technicals

DNTH has the stronger structure
MetricDNTHERAS
RSI (14)62.953.8
ADX (14)26.411.6
Price vs 50-day3.8%4.7%
Price vs 200-day5.6%2.6%
Volatility (1M, annualized)39.4%81.1%

Risk

DNTH is the more resilient
MetricDNTHERAS
Beta0.971.62
Sharpe ratio1.822.29
Sortino ratio3.313.65
Max drawdown-37.8%-59.5%
Current drawdown-20.8%-30.3%
Annualized volatility59.8%102.7%
Value at risk (95%)-4.7%-6.6%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, DNTH or ERAS?

On the Algovestiq AIQ Score, ERAS is the stronger of the two as of Nov 15, 2026, scoring 61 against DNTH's 56. The edge comes from quality and momentum. DNTH is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is DNTH or ERAS the better buy right now?

ERAS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 1 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.

Why does the AIQ Score favor ERAS over DNTH?

The composite weights Quality, Value, Momentum and Risk Resilience. DNTH leads Risk Resilience by 19 points; ERAS leads Quality by 13 points; ERAS leads Momentum by 9 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, DNTH or ERAS?

Analyst price targets imply +46% upside for DNTH and not covered for ERAS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, DNTH or ERAS?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, DNTH or ERAS?

DNTH on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, DNTH or ERAS?

ERAS on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, DNTH or ERAS?

DNTH is the more resilient of the two, so the other name carries the higher downside risk. DNTH on Risk Resilience, by 19 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is DNTH more profitable than ERAS?

DNTH leads on the comparable margin measures — gross margin 97.2% vs 0%; operating margin -86.8% vs 0%; ttm roe -3.8% vs -5.6%.

Is ERAS's lead over DNTH getting stronger or weaker?

ERAS lead: Reversed — DNTH led by 8 AIQ points 30 sessions ago; ERAS now leads by 5. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 3 times in that window, most recently on 2026-11-13, when ERAS moved ahead of DNTH.

What would change the DNTH vs ERAS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DNTH closes the Quality gap — currently 13 points behind, the largest single contributor to ERAS's edge; DNTH's Low Volume Rally Warning resolves — a bearish volume rule currently active against it; ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about DNTH and ERAS?

DNTH: 3 bullish / 2 bearish / 1 neutral, conflicted. ERAS: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DNTH is Golden Cross Active (bullish, long horizon). On ERAS it is Death Cross Active (bearish, long horizon).

Compare DNTH and ERAS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.